Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review

Approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2), providing an actionable target for many different therapies. In the metastatic setting, prognosis has improved greatly with the use of anti-HER2 drugs such as trastuzumab, pertuzumab, and trastuzumab-emt...

Descripción completa

Detalles Bibliográficos
Autores principales: Lebert, Julie, Lilly, Evan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030458/
https://www.ncbi.nlm.nih.gov/pubmed/35448182
http://dx.doi.org/10.3390/curroncol29040208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030458/
https://www.ncbi.nlm.nih.gov/pubmed/35448182
http://dx.doi.org/10.3390/curroncol29040208

Ejemplares similares